Semax: Molecular Structure

Molecular Structure and Properties#

Semax (ACTH(4-7)-PGP) is a synthetic linear heptapeptide with the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was designed by appending a stabilizing C-terminal tripeptide to the bioactive ACTH(4-7) core fragment. This rational design approach produced a peptide that retains the nootropic and neurotrophic properties of the ACTH(4-10) fragment while achieving significantly improved metabolic stability.

Amino Acid Sequence and Composition#

Full Sequence#

The complete sequence of Semax is:

H-Met-Glu-His-Phe-Pro-Gly-Pro-OH

This can be divided into two functional domains:

Individual Residue Analysis#

Methionine (Met, position 1): The N-terminal methionine corresponds to position 4 in the native ACTH sequence. It contains a thioether side chain that is susceptible to oxidation, which is the primary degradation pathway for Semax under oxidative stress conditions. Methionine oxidation to methionine sulfoxide can reduce biological activity.

Glutamic acid (Glu, position 2): Corresponding to ACTH position 5, glutamic acid provides a negatively charged carboxylate side chain at physiological pH. This residue contributes to the peptide's water solubility and may participate in receptor interactions.

Histidine (His, position 3): At ACTH position 6, histidine has an imidazole side chain with a pKa near physiological pH (~6.0), allowing it to exist in both protonated and neutral forms. This residue is potentially important for receptor binding and may coordinate metal ions.

Phenylalanine (Phe, position 4): Corresponding to ACTH position 7, phenylalanine provides a hydrophobic aromatic side chain. This residue is important for the pharmacophore, as aromatic amino acids in melanocortin fragments contribute to receptor recognition.

Proline (Pro, position 5): The first proline of the PGP extension. Proline's cyclic structure introduces a rigid kink in the peptide backbone, restricting conformational freedom and contributing to resistance against proteolytic degradation.

Glycine (Gly, position 6): The smallest amino acid provides conformational flexibility between the two prolines. Glycine's lack of a side chain allows the peptide backbone to adopt conformations that would be sterically prohibited for other residues.

Proline (Pro, position 7): The C-terminal proline provides critical protection against carboxypeptidase degradation. Proline's imino acid structure makes it a poor substrate for most carboxypeptidases, effectively blocking enzymatic degradation from the C-terminus.

Physicochemical Properties#

Molecular Formula Breakdown#

The molecular formula C37H51N9O10S accounts for:

• Carbon: 37 atoms from amino acid backbones and side chains
• Hydrogen: 51 atoms
• Nitrogen: 9 atoms from peptide bonds, histidine imidazole, and amino terminus
• Oxygen: 10 atoms from carboxylate groups, peptide carbonyls, and glutamic acid
• Sulfur: 1 atom from the methionine thioether

The molecular weight of 813.93 Da places Semax well below the typical molecular weight cutoff for intranasal absorption (~1000 Da), which contributes to its effectiveness as an intranasal drug.

The PGP Stabilization Strategy#

Design Rationale#

The native ACTH(4-7) tetrapeptide Met-Glu-His-Phe has a biological half-life of only seconds to minutes in plasma due to rapid degradation by ubiquitous aminopeptidases and carboxypeptidases. This renders the native fragment impractical as a therapeutic agent.

The Pro-Gly-Pro (PGP) extension addresses this limitation through several mechanisms:

1. Carboxypeptidase resistance: The C-terminal proline is a poor substrate for most carboxypeptidases due to its cyclic imino structure. This blocks sequential degradation from the C-terminus.

2. Endopeptidase resistance: The Pro-Gly and Gly-Pro bonds are relatively resistant to many endopeptidases. The combination of proline residues flanking glycine creates a structural motif that is difficult for proteases to cleave.

3. Conformational effects: The proline residues introduce backbone rigidity that may slow enzymatic recognition and processing.

Independent Biological Activity of PGP#

Research has shown that the PGP tripeptide is not merely a metabolically inert stabilizing group. PGP itself has been identified as an endogenous immunomodulatory peptide derived from collagen degradation. It acts as a neutrophil chemoattractant through CXCR2 receptor activation. This independent bioactivity of the PGP moiety may contribute to Semax's immunomodulatory and neuroprotective effects, particularly in the context of cerebral ischemia where the immune response is a critical determinant of outcome.

Structural Comparison with Related Peptides#

Comparison with ACTH Fragments#

The key observation is that Semax achieves enhanced metabolic stability while retaining the nootropic properties of the longer ACTH(4-10) fragment, despite containing only the first four residues of that sequence. This suggests that the PGP extension not only stabilizes the peptide but may also create a pharmacophore that mimics aspects of the longer ACTH fragment's receptor interaction.

Comparison with Selank#

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is another Russian-developed neuropeptide that uses the same PGP stabilization strategy. It is derived from the immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg) rather than ACTH.

Both peptides demonstrate that the PGP stabilization platform is versatile and can be applied to different bioactive tetrapeptide cores to create therapeutically distinct analogs.

Pharmacokinetic Properties#

Absorption#

Semax is administered intranasally, exploiting the nasal mucosa's unique properties for CNS drug delivery. The nasal cavity provides direct access to the brain through two primary pathways:

1. Olfactory nerve pathway: Semax can be transported along olfactory nerve axons from the nasal epithelium directly to the olfactory bulb and subsequently to other brain regions
2. Trigeminal nerve pathway: The maxillary and ophthalmic branches of the trigeminal nerve in the nasal mucosa provide an additional route to the brainstem and brain

The peptide's molecular weight (814 Da) is favorable for nasal absorption, as it falls below the general molecular weight threshold (~1000 Da) for efficient transmucosal absorption.

Distribution#

Semax demonstrates specific binding in the rat brain with a dissociation constant (KD) of 2.4 nM, indicating high-affinity interaction with putative receptor sites. The binding was characterized as time-dependent, specific, reversible, and calcium-dependent. Brain regions showing elevated BDNF protein after Semax administration include the basal forebrain, hippocampus, and frontal cortex, indicating broad CNS distribution.

Metabolism#

Semax is metabolized through sequential peptidase activity. The primary metabolic pathways include:

• Aminopeptidase cleavage from the N-terminus (Met removal)
• Endopeptidase cleavage at various peptide bonds
• The PGP extension slows C-terminal degradation significantly

The serum half-life is reported to be greater than 1 hour, which is dramatically longer than the native ACTH(4-7) fragment (seconds to minutes). However, the biological effects of Semax persist for 2-4 hours after intranasal administration, suggesting tissue binding and sustained receptor activation beyond the period of detectable serum levels.

Excretion#

Metabolic fragments are eliminated primarily through renal excretion. The small molecular weight of both the parent compound and its metabolites facilitates glomerular filtration.

Stability Considerations#

Chemical Stability#

The primary degradation pathway for Semax under storage conditions is methionine oxidation. The Met-1 thioether can be oxidized to methionine sulfoxide by atmospheric oxygen, particularly in the presence of light, heat, or transition metal ions. This oxidation reduces biological activity and is the main concern for long-term storage.

Stability Optimization#

NA-Semax (Acetylated Derivative)#

N-Acetyl Semax (NA-Semax) is a modified form with an acetyl group attached to the N-terminal methionine. This modification provides:

• Enhanced resistance to aminopeptidase degradation
• Extended biological half-life (6-12 hours vs 2-4 hours for Semax)
• Potentially higher CNS bioavailability
• Protection of methionine against oxidation

NA-Semax and NA-Semax-Amidate represent second-generation modifications of the original Semax molecule that are available as research chemicals but are not part of the approved pharmaceutical product in Russia.

Evidence Gaps#

• Crystal structure or NMR solution structure of Semax not published
• Receptor binding site identity at the molecular level not fully characterized
• Exact conformational ensemble adopted by Semax in solution unknown
• Whether the PGP moiety contributes to receptor binding or only to stability is debated
• Quantitative human pharmacokinetic data from controlled studies not available
• Comparative bioavailability between intranasal and subcutaneous routes not formally studied

Related Reading#

• Semax overview and research guide
• Peptides similar to Semax
• Semax research evidence